Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Vizimpro
(United States) [Available]Synonyms :
dacomitinib
Class :
Antineoplastics and Tyrosine Kinase Inhibitor
Brand Name :
Vizimpro
(United States) [Available]Synonyms :
dacomitinib
Class :
Antineoplastics and Tyrosine Kinase Inhibitor
45
mg
Tablet
Oral
once a day
Continue the treatment until disease progression or unacceptable toxicity occurs  
Dose Adjustments
No adjustment recommended in case of renal and liver impairments
histamine h receptor antagonists
it may decrease the serum concentration of dacomitinib
may increase the immunosuppressive effects of corticosteroids
may increase the immunosuppressive effects of corticosteroids
may increase the immunosuppressive effects of corticosteroids
may increase the immunosuppressive effects of corticosteroids
may increase the immunosuppressive effects of corticosteroids
it may decrease the serum concentration of dacomitinib
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
May increase the adverse effect of Sulfonylureas
when both drugs are combined, there may be an increase in the serum concentration of nortriptyline
when both drugs are combined, there may be an increase in the serum concentration of oliceridine
when both drugs are combined, there may be an increase in the serum concentration of olmutinib
when both drugs are combined, there may be an increase in the serum concentration of paroxetine  
when both drugs are combined, there may be an increase in the serum concentration of perhexiline
when both drugs are combined, there may be an increase in the serum concentration of perphenazine 
it may diminish the excretion rate when combined with benzodiazepines, resulting in an enhanced serum level
it may diminish the excretion rate when combined with benzodiazepines, resulting in an enhanced serum level
Combining dacomitinib with pranlukast may cause a reduction in the dacomitinib’s metabolism
When dacomitinib is used together with oleandomycin, this leads to enhanced concentration serum of dacomitinib
When dacomitinib is used together with ridaforolimus, this leads to enhanced concentration serum of dacomitinib
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
When dacomitinib is used together with oliceridine, this leads to enhanced concentration serum of oliceridine
The human epidermal growth factor receptor family tyrosine kinases are inhibited by the irreversible small drug dacomitinib.Â
It binds covalently to the cysteine residues in the HER receptors’ catalytic domains to produce irreversible inhibition.Â
Through the activation of downstream signal transduction pathways, the ErbB or epidermal growth factor (EGF) family contributes to tumor growth, metastasis, and treatment resistance.Â
The EGFR gene increases in about 40% of cases, and the EGFRvIII mutation, which is a deletion that results in a persistent activation of the receptor’s tyrosine kinase domain is present in 50% of cases.Â
Adverse drug reactions: Â
Frequency defined Â
>10%  Â
Asthenia  Â
Mouth ulceration   Â
Musculoskeletal pain   Â
Upper respiratory tract infection  Â
Diarrhea  Â
Rash   Â
Paronychia   Â
Stomatitis  Â
Anemia   Â
Cough   Â
Conjunctivitis  Â
Nausea   Â
Hyperbilirubinemia   Â
Dyspnea   Â
Constipation  Â
Dermatitis   Â
Insomnia   Â
1-10%   Â
Skin fissures  Â
Dysgeusia  Â
Skin exfoliation/exfoliative skin reactions  Â
Interstitial lung disease  Â
Keratitis  Â
Chest pain   Â
Fatigue  Â
Vomiting  Â
Â
None
Contraindication:Â
None Â
Caution:Â
Interstitial Lung DiseaseÂ
Dermatologic ReactionsÂ
Elevated Liver EnzymesÂ
Pregnancy warnings:    Â
Breastfeeding warnings: Â
Pregnancy Categories:      Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.      Â
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women      Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women      Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits      Â
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.      Â
Category N: There is no data available for the drug under this category
Dacomitinib appears to enhance both the activity in cell lines with resistance mutations and the inhibition of the epidermal growth factor receptor kinase domain, according to preclinical findings.Â
A 5% objective response rate, a 2.8-month progression-free survival, and a 9.5-month overall survival were observed in clinical trials including patients with advanced non-small cell lung cancer who advanced following treatment.Â
In patients with EGFR-activating mutations with advanced or metastatic non-small cell lung cancer, phase III clinical studies (ARCHER 1050) shown a notable improvement in progression-free survival in comparison to gefitinib.Â
It is taken orally in tablet form with food.Â
Administer daily at the same time, with or without food.Â
Continue with the next planned dose if the patient misses a dose or throws up instead of taking an extra dose or making up a missing one.Â
Patient information leafletÂ
Generic Name: dacomitinibÂ
Why do we use dacomitinib?Â
Patients with epidermal growth factor receptor (EGFR)-positive metastatic non-small cell lung cancer (NSCLC) should start dacomitinib as their first line of treatment.Â
The most common cause of cancer-related deaths is lung cancer, with 85% of cases being NSCLC. Of the patients with non-small cell lung cancer (NSCLC), over 75% had a late diagnosis with advanced and metastatic illness, resulting in a 5% survival rate.Â
A mutation in EGFR is responsible for about 60% of NSCLC cases, and EGFR overexpression is linked to poor chemosensitivity and frequent lymph node metastases.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
